

Prof. YILMAZ ÇAPAN

Personal Information

Office Phone: [+90 444 8 548](tel:+904448548)

Email: yilmaz.capan@lokmanhekim.edu.tr

Web: <https://avesis.lokmanhekim.edu.tr/yilmaz.capan>

International Researcher IDs

ScholarID: Lgci69EAAAAJ

ORCID: 0000-0003-1234-9018

Publons / Web Of Science ResearcherID: AAM-5292-2021

ScopusID: 6603768177

Yoksis Researcher ID: 105883

Education Information

Doctorate, Universite de Lille II, Eczacılık Teknolojisi, France 1973 - 1978

Undergraduate, Hacettepe University, Eczacılık Fakültesi, Eczacılık Pr. (4 Yıllık), Turkey 1967 - 1972

Foreign Languages

French, C1 Advanced

English, C1 Advanced

Research Areas

Health Sciences, Pharmacology and Therapeutics, Pharmaceutics Technology

Academic Titles / Tasks

Professor, Lokman Hekim University, Eczacılık Fakültesi, Eczacılık Teknolojisi Bölümü, 2020 - Continues

Professor, Hacettepe University, Eczacılık Fakültesi, Eczacılık Teknolojisi Bölümü, 1990 - 2017

Associate Professor, Hacettepe University, Eczacılık Fakültesi, Eczacılık Teknolojisi Bölümü, 1985 - 1990

Assistant Professor, Hacettepe University, Eczacılık Fakültesi, Eczacılık Teknolojisi Bölümü, 1979 - 1985

Academic and Administrative Experience

BAP Scientific Commissioner, Lokman Hekim University, Eczacılık Fakültesi, 2021 - Continues

University Executive Board Member, Lokman Hekim University, Rektörlük, 2021 - Continues

Lokman Hekim Üniversitesi Kariyer Birimi Yönetim Kurulu Üyesi, Lokman Hekim University, Rektörlük, 2021 - Continues

Eczacılık Fakültesi Senato Temsilcisi, Lokman Hekim University, Eczacılık Fakültesi, 2021 - Continues

Eczacılık-endüstri iş birliği komisyonu, Lokman Hekim University, Eczacılık Fakültesi, 2021 - Continues

Değişim Programları (Erasmus+vb.) Değerlendirme Komisyonu, Lokman Hekim University, Rektörlük, 2021 - Continues

Head of Department, Lokman Hekim University, Eczacılık Fakültesi, Eczacılık Teknolojisi Bölümü, 2020 - Continues

Head of Department, Hacettepe University, Eczacılık Fakültesi, Farmasotik Teknoloji Bölümü, 2007 - 2010

Courses

İYİ İLAÇ İMAL TEKNİĞİ VE KALİTE GÜVENLİĞİNİN SAĞLANMASI, Postgraduate, 2023 - 2024, 2022 - 2023, 2021 - 2022
FARMASÖTİK PROSES VALİDASYONU, Postgraduate, 2023 - 2024, 2022 - 2023
MODİFİYE SALIM SAĞLAYAN KATI ORAL DOZAJ ŞEKİLLERİ, Postgraduate, 2023 - 2024, 2022 - 2023
İlaç Taşıyıcı Yeni Sistemler, Postgraduate, 2023 - 2024, 2022 - 2023, 2021 - 2022
Pharmaceutical Technology I, Undergraduate, 2023 - 2024
Farmasötik Teknoloji IV, Undergraduate, 2022 - 2023
YÜKSEK LİSANS TEZ ÇALIŞMASI, Postgraduate, 2023 - 2024
Farmasötik Teknoloji I, Undergraduate, 2023 - 2024, 2022 - 2023, 2021 - 2022, 2020 - 2021
Farmasötik Teknoloji Lab. II, Undergraduate, 2022 - 2023, 2021 - 2022, 2020 - 2021
Pharmaceutical Technology Lab. I, Undergraduate, 2023 - 2024
Farmasötik Geliştirme Çalışmaları, Postgraduate, 2023 - 2024, 2022 - 2023, 2021 - 2022, 2020 - 2021
Farmasötik Teknoloji Lab. III, Undergraduate, 2023 - 2024, 2022 - 2023, 2021 - 2022
Mezuniyet Projesi Dersi I, Undergraduate, 2023 - 2024, 2022 - 2023
Farmasötik Teknoloji II, Undergraduate, 2022 - 2023
Nanoteknoloji, Undergraduate, 2023 - 2024
İlaç Şekilleri ve Tıbbi Malzeme, Associate Degree, 2023 - 2024, 2022 - 2023, 2021 - 2022
Farmasötik Teknoloji Lab IV, Undergraduate, 2022 - 2023, 2021 - 2022
YÜKSEK LİSANS TEZ ÇALIŞMASI, Postgraduate, 2023 - 2024
Farmasötik Teknoloji Lab. I, Undergraduate, 2023 - 2024, 2022 - 2023, 2021 - 2022, 2020 - 2021
Farmasötik Teknoloji III, Undergraduate, 2023 - 2024, 2022 - 2023, 2021 - 2022
TIBBİ ÜRÜNLERDE RUHSATLANDIRMA VE PATENT UYGULAMALARI, Undergraduate, 2022 - 2023

Advising Theses

ÇAPAN Y., Polisorbat 80 kaplı, kurkumin ve dosetaksel yüklü PLGA nanopartiküller sistemlerin geliştirilmesi ve beyin tümörü etkinliklerinin değerlendirilmesi, Doctorate, I.SEKO(Student), 2020
ÇAPAN Y., Beyine hedeflendirilmiş bevasizumab yüklü nanopartiküler ilaç taşıyıcı sistemlerin hazırlanması ve etkinliklerinin değerlendirilmesi, Doctorate, S.AKBAŞ(Student), 2020
ÇAPAN Y., Doksorubisin ve elakridar içeren PLGA/silika hibrit nanopartiküllerin formülasyonu ve meme kanserindeki etkinliğinin değerlendirilmesi, Doctorate, H.TONBUL(Student), 2019
ÇAPAN Y., İçi boşluklu gözenekli nanopartiküllerin ilaç taşıyıcı sistem olarak hazırlanması ve incelenmesi, Doctorate, G.ULTAV(Student), 2019
ÇAPAN Y., Donepezil yüklü nanopartiküler ilaç taşıyıcı sistemlerin hazırlanması ve in vitro değerlendirilmesi, Postgraduate, S.ŞAHAN(Student), 2018
ÇAPAN Y., Kemik metastazlarının tedavisinde etkili nanopartikül formülasyonlarının geliştirilmesi, optimizasyonu ve in vitro değerlendirilmesi, Doctorate, S.KOZLU(Student), 2017
ÇAPAN Y., Polimerik nanopartiküllerin partikül büyüklüğüne bağlı olarak hücre içine alım kinetikleri ve mekanizmaları, Doctorate, A.ŞAHİN(Student), 2017
ÇAPAN Y., Glioma tedavisinde nanopartikül formülasyonlarının geliştirilmesi, in vitro ve in vivo etkinliğinin değerlendirilmesi, Doctorate, S.TOKTAŞ(Student), 2016
ÇAPAN Y., Dosetaksel içeren nanopartiküllerin formülasyonu ve in vitro değerlendirilmesi, Postgraduate, D.DEMİR(Student), 2013
ÇAPAN Y., Hemen salım sağlayan kandesartan sileksetil tablet formülasyonuna tasarımla kalite uygulaması, Doctorate, M.YÜCE(Student), 2013
ÇAPAN Y., Paklitaksel nanopartiküllerinin kalite tasarımı ile geliştirilmesi ve değerlendirilmesi, Doctorate,

F.YERLİKAYA(Student), 2013

ÇAPAN Y., Paklitaksel içeren nanopartiküllerin formülasyonu ve in vitro değerlendirilmesi, Postgraduate, G.AYGÜL(Student), 2011

ÇAPAN Y., Beyne hedeflendirilmiş kaspaz inhibitörleri ve bazik fibroblast büyüme faktörü (bFGF) taşıyan nanopartiküllerin hazırlanması, beyne geçişinin ve etkinliğinin değerlendirilmesi, Postgraduate, S.ÇABAN(Student), 2010

ÇAPAN Y., Polimorfizm gösteren etkin maddenin farmasötik kokristallerinin hazırlanması ve in vitro değerlendirilmesi üzerine çalışmalar, Postgraduate, P.RENKOĞLU(Student), 2010

ÇAPAN Y., Sitotoksik beyin ödemi tedavisine yönelik akuaporin 4 antisense oligonükleotid yüklü, beyne hedeflendirilmiş nanopartiküler sistem tasarımı, Postgraduate, S.KOZLU(Student), 2010

ÇAPAN Y., Serbest radikal temizleyici madde içeren nanopartiküler taşıyıcı sistemlerin tasarımı ve değerlendirilmesi, Postgraduate, K.ÖZTÜRK(Student), 2010

ÇAPAN Y., Klozapin içeren ağızda dağılan tablet formülasyonu geliştirilmesi, in vitro ve in vivo yöntemlerle değerlendirilmesi, Doctorate, S.SEVTAP(Student), 2010

ÇAPAN Y., Advanced technology: Regulatory requirements during the development and marketing phase of nanotechnology medicines, Postgraduate, N.TUĞBA(Student), 2009

ÇAPAN Y., Alfa-Fenil-N-Tert-Butil-Nitron (PBN) yüklü nanopartiküler taşıyıcı sistemlerin hazırlanması ve in vitro olarak değerlendirilmesi, Postgraduate, O.PINARBAŞLI(Student), 2008

ÇAPAN Y., Oral uygulama için salmon kalsitoninin biyotin konjugat sisteminin hazırlanması ve in vitro/in vivo değerlendirilmesi, Doctorate, M.ÇETİN(Student), 2006

ÇAPAN Y., Sodyum alendronat içeren oral konvansiyonel tabletler üzerinde önerilen teknolojik parametrelerin değerlendirilmesi, Postgraduate, M.BİNGÖL(Student), 2005

ÇAPAN Y., Kaspaz inhibitörlerinin beyne hedeflendirilmesi için nanopartiküler taşıyıcı sistemlerin hazırlanması, Doctorate, Y.AKTAŞ(Student), 2005

ÇAPAN Y., Antisens oligonükleotidlerin taşınmasında nanopartiküler sistemlerin hazırlanması ve karakterizasyonu, Postgraduate, A.CİHAN(Student), 2004

ÇAPAN Y., Beyin tümörlerinin tedavisine yönelik mitoksantron içeren mikropartiküler sistemlerin tasarımı ve değerlendirilmesi, Doctorate, S.BOZDAĞ(Student), 2003

ÇAPAN Y., Bazik fibroblast büyüme faktörü (bFGF) taşıyan mikropartiküler ilaç taşıyıcı sistemlerin hazırlanması ve karakterizasyonu, Postgraduate, M.ÇETİN(Student), 2003

ÇAPAN Y., In vitro - in vivo evaluation of carbamazepine conventional tablets, Postgraduate, R.ELQİDRA(Student), 2001

ÇAPAN Y., Karbamazepin içeren kontrollü salım sağlayan (oral ve biyoadheziv) tabletlerin formülasyonu ve in vitro/in vivo değerlendirilmesi, Postgraduate, G.İKİNCİ(Student), 1997

ÇAPAN Y., Kaptopril içeren bukoadheziv tabletlerin formülasyonu ve in vitro/ in vivo değerlendirilmesi, Postgraduate, Y.YAZIKSIZ(Student), 1996

ÇAPAN Y., Sürekli salım sağlayan furosemid tabletlerinin formülasyonu ve biyoyararlanımının değerlendirilmesi, Postgraduate, F.SEYYED(Student), 1993

ÇAPAN Y., Morfin sülfat içeren bukoadheziv tablet formülasyonlarının tasarımı: in vitro-in vivo değerlendirmeler, Postgraduate, Ş.ANLAR(Student), 1992

ÇAPAN Y., Sürekli salınma sağlayan potasyum klorür tabletlerinin formülasyonu ve in vitro-in vivo değerlendirilmesi, Doctorate, S.ŞENEL(Student), 1989

ÇAPAN Y., Sürekli salınma sağlayan lityum karbonat tabletlerinin formülasyon ve invivo in vitro değerlendirilmesi, Postgraduate, K.ÇİFTÇİ(Student), 1988

Jury Memberships

Associate Professor Exam, Associate Professor Exam, Lokman Hekim University, August, 2021

Associate Professor Exam, Associate Professor Exam, Lokman Hekim Üniversitesi, May, 2021

Published journal articles indexed by SCI, SSCI, and AHCI

- I. **Structural and Functional Analysis of CEX Fractions Collected from a Novel Avastin® Biosimilar Candidate and Its Innovator: A Comparative Study**
Gurel B., Berksoz M., Capkin E., Parlar A., Pala M. C., Ozkan A., ÇAPAN Y., Daglikoca D. E., Yuce M.
Pharmaceutics, vol.14, no.8, 2022 (SCI-Expanded)
- II. **Preface**
ÇAPAN Y., Sahin A., TONBUL H.
Drug Delivery with Targeted Nanoparticles: In Vitro and in Vivo Evaluation Methods, vol.30, 2021 (SCI-Expanded)
- III. **Development of curcumin and docetaxel co-loaded actively targeted PLGA nanoparticles to overcome blood brain barrier**
Seko I., TONBUL H., Tavukcuoglu E., Sahin A., Akbas S., Yanik H., ÖZTÜRK S. C., ESENDAĞLI G., Khan M., ÇAPAN Y.
JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY, vol.66, 2021 (SCI-Expanded)
- IV. **Folic acid decoration of mesoporous silica nanoparticles to increase cellular uptake and cytotoxic activity of doxorubicin in human breast cancer cells**
TONBUL H., Sahin A., Tavukcuoglu E., Ultav G., AKBAŞ S., AKTAŞ Y., ESENDAĞLI G., ÇAPAN Y.
JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY, vol.63, 2021 (SCI-Expanded)
- V. **Fractionated charge variants of biosimilars: A review of separation methods, structural and functional analysis**
Yuce M., Sert F., Torabfam M., Parlar A., Gurel B., Cakir N., Daglikoca D. E., Khan M. A., ÇAPAN Y.
ANALYTICA CHIMICA ACTA, vol.1152, 2021 (SCI-Expanded)
- VI. **pH-sensitive chitosan-PEG-decorated hollow mesoporous silica nanoparticles could be an effective treatment for acute myeloid leukemia (AML)**
Ultav G., TONBUL H., Tavukcuoglu E., ÖZTÜRK S., Akbas S., Sahin A., ESENDAĞLI G., ÇAPAN Y.
Journal of Nanoparticle Research, vol.24, no.2, 2021 (SCI-Expanded)
- VII. **Combination of Paclitaxel and R-flurbiprofen loaded PLGA nanoparticles suppresses glioblastoma growth on systemic administration**
Caban-Toktas S., Sahin A., Lule S., Esendagli G., Vural I., Karlı Oguz K., Soylemezoglu F., Mut M., Dalkara T., Khan M., et al.
International Journal of Pharmaceutics, vol.578, 2020 (SCI-Expanded)
- VIII. **Combination drug delivery with actively-targeted PLGA nanoparticles to overcome multidrug resistance in breast cancer**
Tonbul H., Sahin A., Tavukcuoglu E., ESENDAĞLI G., ÇAPAN Y.
JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY, vol.54, 2019 (SCI-Expanded)
- IX. **Preclinical evaluation of a biobetter candidate: Pharmacokinetics and pharmacodynamics of GX-G3 in healthy and neutropenia-induced rats**
Kim Y. J., Ertan-Ahmed S., ÇAPAN Y., Yang S. I.
Drug Development Research, vol.80, no.6, pp.807-813, 2019 (SCI-Expanded)
- X. **Synthesis of Small-Sized Mesoporous Silica Nanoparticles by Experimental Design and Characterization for Further Drug Delivery**
TONBUL H., Ultav G., AKBAŞ S., Sahin A., AKTAŞ Y., ÇAPAN Y.
LATIN AMERICAN JOURNAL OF PHARMACY, vol.38, no.11, pp.2204-2210, 2019 (SCI-Expanded)
- XI. **Nano-Based Carriers for Brain Drug Delivery**
ÖZTÜRK ATAR K., Ozkan M. Y., EROĞLU H., ÇAPAN Y.
CHARACTERIZATION AND BIOLOGY OF NANOMATERIALS FOR DRUG DELIVERY: NANOSCIENCE AND NANOTECHNOLOGY IN DRUG DELIVERY, pp.563-586, 2019 (SCI-Expanded)
- XII. **Nanopharmaceuticals as Drug-Delivery Systems: For, Against, and Current Applications**
ÇALIŞ S., ÖZTÜRK ATAR K., ARSLAN F. N., EROĞLU H., ÇAPAN Y.
NANOCARRIERS FOR DRUG DELIVERY: NANOSCIENCE AND NANOTECHNOLOGY IN DRUG DELIVERY, pp.133-154, 2019 (SCI-Expanded)
- XIII. **Simultaneous Determination of Dexpanthenol, Lidocaine Hydrochloride, Mepyramine Maleate and**

their Related Substances by a RP-HPLC Method in Topical Dosage Forms

Doganay A., Koksel B., Gundogdu S., ÇAPAN Y.

Journal of chromatographic science, vol.56, no.10, pp.903-911, 2018 (SCI-Expanded)

- XIV. **Characterization of bevacizumab by dynamic light scattering while maintaining its native structure**
Akbas S., Sahin A., ÇALIŞ S., Oncel H., ÇAPAN Y.
PHARMAZIE, vol.73, no.7, pp.369-374, 2018 (SCI-Expanded)
- XV. **Development and in vitro evaluation of doxorubicin and celecoxib co-loaded bone targeted nanoparticles**
Kozlu S., Sahin A., Ultav G., Yerlikaya F., ÇALIŞ S., ÇAPAN Y.
JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY, vol.45, pp.213-219, 2018 (SCI-Expanded)
- XVI. **Preparation and Characterization of Biocompatible Chitosan Nanoparticles for Targeted Brain Delivery of Peptides**
Yemisci M., Caban S., Fernandez-Megia E., ÇAPAN Y., Couvreur P., DALKARA T.
NEUROTROPHIC FACTORS: METHODS AND PROTOCOLS, 2ND EDITION, vol.1727, pp.443-454, 2018 (SCI-Expanded)
- XVII. **Development and validation of a LC-FL method for the simultaneous determination of doxorubicin and celecoxib in nanoparticulate fixed dose combination (NanoFDC)**
Kozlu S., ŞAHİN A. E., ÇALIŞ S., ÇAPAN Y.
PHARMAZIE, vol.72, no.10, pp.568-570, 2017 (SCI-Expanded)
- XVIII. **DEVELOPMENT AND VALIDATION OF HPLC ANALYTICAL METHODS USED FOR DETERMINATION OF ASSAY, CONTENT UNIFORMITY AND DISSOLUTION OF IMMEDIATE RELEASE CANDESARTAN CILEXETIL 32 MG TABLETS**
YÜCE M., ÇAPAN Y.
ACTA POLONIAE PHARMACEUTICA, vol.74, no.2, pp.357-367, 2017 (SCI-Expanded)
- XIX. **Evaluation of brain-targeted chitosan nanoparticles through blood-brain barrier cerebral microvessel endothelial cells**
Sahin A., Yoyen-Ermis D., Caban-Toktas S., Horzum U., AKTAŞ Y., Couvreur P., ESENDAĞLI G., ÇAPAN Y.
JOURNAL OF MICROENCAPSULATION, vol.34, no.7, pp.659-666, 2017 (SCI-Expanded)
- XX. **A small variation in average particle size of PLGA nanoparticles prepared by nanoprecipitation leads to considerable change in nanoparticles' characteristics and efficacy of intracellular delivery**
ŞAHİN A., ESENDAĞLI G., YERLİKAYA F., Caban-Toktas S., Yoyen-Ermis D., HORZUM U., AKTAŞ Y., Khan M., Couvreur P., ÇAPAN Y.
ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY, vol.45, no.8, pp.1657-1664, 2017 (SCI-Expanded)
- XXI. **Using PVA and TPGS as combined emulsifier in nanoprecipitation method improves characteristics and anticancer activity of ibuprofen loaded PLGA nanoparticles**
Sahin A., Spiroux F., Guedon I., Arslan F., Sarcan E., Ozkan T., Colak N., Yuksel S., Ozdemir S., Ozdemir B., et al.
Pharmazie, vol.72, no.9, pp.525-528, 2017 (SCI-Expanded)
- XXII. **Preformulation of Immediate Release Candesartan Cilexetil Tablets Using Full Factorial Experimental Design**
YÜCE M., Guven O., KARAHAN S., Saracbası O., ÇAPAN Y.
LATIN AMERICAN JOURNAL OF PHARMACY, vol.35, no.5, pp.921-930, 2016 (SCI-Expanded)
- XXIII. **Systemically administered brain-targeted nanoparticles transport peptides across the blood-brain barrier and provide neuroprotection**
Yemisci M., Caban S., Gursoy-Ozdemir Y., Lule S., NOVOA-CARBALLAL R., RIGUERA R., FERNANDEZ-MEGIA E., Andrieux K., COUVREUR P., ÇAPAN Y., et al.
JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, vol.35, no.3, pp.469-475, 2015 (SCI-Expanded)
- XXIV. **Squalenoyl adenosine nanoparticles provide neuroprotection after stroke and spinal cord injury**
Gaudin A., YEMİŞÇİ ÖZKAN M., EROĞLU H., Lepetre-Mouelhi S., Turkoglu O. F., DEMİR B. N., Caban S., Sargon M. F., Garcia-Argote S., Pieters G., et al.
NATURE NANOTECHNOLOGY, vol.9, no.12, pp.1054-1062, 2014 (SCI-Expanded)
- XXV. **An aquaporin 4 antisense oligonucleotide loaded, brain targeted nanoparticulate system design**

- KOZLU S., CABAN S., YERLIKAYA F., FERNANDEZ-MEGIA E., NOVOA-CARBALLAL R., RIGUERA R., Yemisci M., GURSOY-OZDEMIR Y., DALKARA T., COUVREUR P., et al.
PHARMAZIE, vol.69, no.5, pp.340-345, 2014 (SCI-Expanded)
- XXVI. **Comparative in vitro studies on PBN loaded nanoparticles prepared by biodegradable chitosan, PLGA polymers and their PEGylated block copolymers**
Ozturk K., FERNANDEZ-MEGIA E., NOVOA-CARBALLAL R., RIGUERA R., Yemisci M., GURSOY-OZDEMIR Y., DALKARA T., COUVREUR P., ÇAPAN Y.
JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY, vol.24, no.2, pp.148-152, 2014 (SCI-Expanded)
- XXVII. **Development and Evaluation of Paclitaxel Nanoparticles Using a Quality-by-Design Approach**
Yerlikaya F., Ozgen A., VURAL İ., Guven O., Karaagaoglu E., Khan M. A., ÇAPAN Y.
JOURNAL OF PHARMACEUTICAL SCIENCES, vol.102, no.10, pp.3748-3761, 2013 (SCI-Expanded)
- XXVIII. **Formulation and evaluation of clozapine orally disintegrating tablets prepared by direct compression**
OLMEZ S. S., VURAL İ., ŞAHİN S., ERTUĞRUL A., ÇAPAN Y.
PHARMAZIE, vol.68, no.2, pp.110-116, 2013 (SCI-Expanded)
- XXIX. **CHARACTERIZATION, CELL PROLIFERATION AND CYTOTOXICITY EVALUATION OF VASCULAR ENDOTHELIAL GROWTH FACTOR LOADED POLY (LACTIC-CO-GLYCOLIC ACID) MICROSPHERES**
KERİMOĞLU O., ALARÇIN E., Turkoglu M., Dortunc B., Karagoz H., Ulkur E., VURAL İ., ÇAPAN Y.
NOBEL MEDICUS, vol.8, no.1, pp.77-82, 2012 (SCI-Expanded)
- XXX. **TRANSPORT OF A CASPASE INHIBITOR ACROSS THE BLOOD BRAIN BARRIER BY CHITOSAN NANOPARTICLES**
YEMISCI M., GURSOY-OZDEMIR Y., CABAN S., BODUR E., ÇAPAN Y., DALKARA T.
NANOMEDICINE: CANCER, DIABETES, AND CARDIOVASCULAR, CENTRAL NERVOUS SYSTEM, PULMONARY AND INFLAMMATORY DISEASES, vol.508, pp.253-269, 2012 (SCI-Expanded)
- XXXI. **Evaluation of drug-exciipient interaction in the formulation of celecoxib tablets**
Bozdog-Pehlivan S., Subasi B., VURAL İ., Unlu N., ÇAPAN Y.
Acta Poloniae Pharmaceutica - Drug Research, vol.68, no.3, pp.423-433, 2011 (SCI-Expanded)
- XXXII. **Comparative evaluation of in vitro parameters of tamoxifen citrate loaded poly(lactide-co-glycolide), poly(ϵ -caprolactone) and chitosan nanoparticles**
Cirpanli Y., Yerlikaya F., Ozturk K., Erdogan N., Launay M., Gegu C., Leturgez T., BİLENSOY E., ÇALIŞ S., ÇAPAN Y.
Pharmazie, vol.65, no.12, pp.867-870, 2010 (SCI-Expanded)
- XXXIII. **The influence of technological parameters on the physicochemical properties of blank PLGA nanoparticles**
ÖZTÜRK K., Caban S., Kozlu S., Kadayifci E., YERLİKAYA F., ÇAPAN Y.
Pharmazie, vol.65, no.9, pp.665-669, 2010 (SCI-Expanded)
- XXXIV. **LC-UV Determination of Melatonin from Chitosan Nanoparticles**
Yerlikaya F., Aktas Y., ÇAPAN Y.
CHROMATOGRAPHIA, vol.71, pp.967-970, 2010 (SCI-Expanded)
- XXXV. **A nanomedicine transports a peptide caspase-3 inhibitor across the blood-brain barrier and provides neuroprotection**
KARATAS H., AKTAS Y., GURSOY-OZDEMIR Y., BODUR E., YEMISCI M., CABAN S., VURAL A., PINARBASLI O., ÇAPAN Y., FERNANDEZ-MEGIA E., et al.
Journal of Neuroscience, vol.29, no.44, pp.13761-13769, 2009 (SCI-Expanded)
- XXXVI. **ANALYTICAL METHOD DEVELOPMENT AND VALIDATION OF TAMOXIFEN CITRATE USING NORMAL PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY**
Yerlikaya F., Launay M., Gegu C., Leturgez T., BİLENSOY E., ÇALIŞ S., ÇAPAN Y.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, vol.38, no.1, pp.183-184, 2009 (SCI-Expanded)
- XXXVII. **Microbiological and clinical comparison of chlorhexidine buccoadhesive tablet and chlorhexidine mouthrinse**
AKTAŞ A., GIRAY B., ÇAPAN Y., MENEMENLIOĞLU D., HAYRAN M., İKİNCİ G., VURAL İ.
JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY, vol.19, no.5, pp.353-357, 2009 (SCI-Expanded)

- XXXVIII. **Preparation and evaluation of alpha-phenyl-n-tert-butyl nitron (PBN)-encapsulated chitosan and PEGylated chitosan nanoparticles**
Pinarbasli O, AKTAŞ Y, DALKARA T, Andrieux K, Alonso M, Fernandez-Megia E, Novoa-Carballal R, Riguera R, Couvreur P, ÇAPAN Y.
Pharmazie, vol.64, no.7, pp.436-439, 2009 (SCI-Expanded)
- XXXIX. **Preparation and Characterization of Salmon Calcitonin-biotin Conjugates**
ÇETİN M, Youn Y. S, ÇAPAN Y, Lee K. C.
AAPS PHARMSCITECH, vol.9, no.4, pp.1191-1197, 2008 (SCI-Expanded)
- XL. **Preparation and in vitro evaluation of bFGF-loaded chitosan nanoparticles**
Cetin M, AKTAŞ Y, VURAL İ, ÇAPAN Y, DOĞAN A, DUMAN M, DALKARA T.
Drug Delivery, vol.14, no.8, pp.525-529, 2007 (SCI-Expanded)
- XLI. **Stability of antimicrobial decapeptide (KSL) and its analogues for delivery in the oral cavity**
Na D. H., Faraj J., Capan Y., Leung K. P., DeLuca P. P.
PHARMACEUTICAL RESEARCH, vol.24, no.8, pp.1544-1550, 2007 (SCI-Expanded)
- XLII. **Development of a peptide-containing chewing gum as a sustained release antiplaque antimicrobial delivery system**
Faraj J. A., Dorati R., Schoubben A., Worthen D., Selmin F., Capan Y., Leung K., DeLuca P. P.
AAPS PHARMSCITECH, vol.8, no.1, 2007 (SCI-Expanded)
- XLIII. **Treatment of malignant gliomas with mitoxantrone-loaded poly (lactide-co-glycolide) microspheres**
YEMİŞÇİ ÖZKAN M., PEHLİVAN S., Çetin M., Söylemezoglu F., ÇAPAN Y., DALKARA T., VURAL İ.
Neurosurgery, vol.59, no.6, pp.1296-1302, 2006 (SCI-Expanded)
- XLIV. **Preparation and characterization of PLGA nanospheres for the targeted delivery of NR2B-specific antisense oligonucleotides to the NMDA receptors in the brain**
KİLİC A. C., Capan Y., Vural I., Gursoy R. N., Dalkara T., CUİNE A., HİNCAL A. A.
JOURNAL OF MICROENCAPSULATION, vol.22, no.6, pp.633-641, 2005 (SCI-Expanded)
- XLV. **Development and brain delivery of chitosan-PEG nanoparticles functionalized with the monoclonal antibody OX26**
AKTAŞ Y., YEMİŞÇİ ÖZKAN M., Andrieux K., Gursoy R., Alonso M., Fernandez-Megia E., Novoa-Carballal R., Quinoa E., Riguera R., Sargon M., et al.
BIOCONJUGATE CHEMISTRY, vol.16, no.6, pp.1503-1511, 2005 (SCI-Expanded)
- XLVI. **Chewing gum of antimicrobial decapeptide (KSL) as a sustained antiplaque agent: Preformulation study**
Na D., Faraj J., ÇAPAN Y., Leung K., DeLuca P.
JOURNAL OF CONTROLLED RELEASE, vol.107, no.1, pp.122-130, 2005 (SCI-Expanded)
- XLVII. **Preparation and characterization of bFGF and BSA-loaded microspheres**
ÇETİN M., ÇAPAN Y., Vural I., Dogan A., Guc D., Hincal A., Wehrle P., Dalkara T.
JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY, vol.15, no.5, pp.371-375, 2005 (SCI-Expanded)
- XLVIII. **Preparation and in vitro evaluation of chitosan nanoparticles containing a caspase inhibitor**
AKTAŞ Y., ANDRIEUX K., ALONSO M. J., CALVO P., Gursoy R. N., COUVREUR P., Capan Y.
INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol.298, no.2, pp.378-383, 2005 (SCI-Expanded)
- XLIX. **Formulation and in vitro bioactivity of mitoxantrone-loaded biodegradable microspheres on rat glioma (RG2) cells**
PEHLİVAN S., ÇAPAN Y., DALKARA T., DOĞAN A., Guc D., Hincal A., Deluca P.
Journal of Drug Delivery Science and Technology, vol.15, no.3, pp.201-206, 2005 (SCI-Expanded)
- L. **In vitro cytotoxicity of mitoxantrone-incorporated albumin microspheres on acute promyelocytic leukaemia cells**
Bozdog S., ÇAPAN Y., Vural I., Dalkara T., Dogan A., Guc D., Hincal A., Deluca P.
JOURNAL OF MICROENCAPSULATION, vol.21, no.7, pp.751-760, 2004 (SCI-Expanded)
- LI. **Effect of polymorphism on in vitro in vivo properties of carbamazepine conventional tablets**
Elqidra R., Unlu N., ÇAPAN Y., Sahin G., Dalkara T., Hincal A.
JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY, vol.14, no.2, pp.147-153, 2004 (SCI-Expanded)

- LII. **In vitro/in vivo studies on a buccal bioadhesive tablet formulation of carbamazepine**
Ikinci G., ÇAPAN Y., ŞENEL S., Alaaddinoglu E., DALKARA T., Hincal A.
Pharmazie, vol.55, no.10, pp.762-765, 2000 (SCI-Expanded)
- LIII. **Stability of poly(L-lysine)-complexed plasmid DNA during mechanical stress and DNase I treatment**
Capan Y., Woo B., Gebrekidan S., Ahmed S., DeLuca P.
PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY, vol.4, no.4, pp.491-498, 1999 (SCI-Expanded)
- LIV. **Influence of formulation parameters on the characteristics of poly(D,L-lactide-co-glycolide) microspheres containing poly(L-lysine) complexed plasmid DNA**
Capan Y., Woo B., Gebrekidan S., Ahmed S., DeLuca P.
JOURNAL OF CONTROLLED RELEASE, vol.60, no.2-3, pp.279-286, 1999 (SCI-Expanded)
- LV. **Preparation and characterization of poly (D,L-lactide-co-glycolide) microspheres for controlled release of poly(L-lysine) complexed plasmid DNA**
ÇAPAN Y., Woo B., Gebrekidan S., Ahmed S., DeLuca P.
PHARMACEUTICAL RESEARCH, vol.16, no.4, pp.509-513, 1999 (SCI-Expanded)
- LVI. **Formulation and in vitro in vivo investigation of carbamazepine controlled-release matrix tablets**
Ikinci G., Capan Y., Senel S., Dalkara T., Hincal A.
PHARMAZIE, vol.54, no.2, pp.139-141, 1999 (SCI-Expanded)
- LVII. **Histological and bioadhesion studies on buccal bioadhesive tablets containing a penetration enhancer sodium glycodeoxycholate**
Senel S., Capan Y., Sargon M. F., Giray C. B., Hincal A.
INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol.170, no.2, pp.239-245, 1998 (SCI-Expanded)
- LVIII. **In vitro studies on enhancing effect of sodium glycocholate on transbuccal permeation of morphine hydrochloride**
Senel S., Duchene D., Hincal A., Capan Y., Ponchel G.
JOURNAL OF CONTROLLED RELEASE, vol.51, pp.107-113, 1998 (SCI-Expanded)
- LIX. **Enhancement of transbuccal permeation of morphine sulfate by sodium glycodeoxycholate in vitro**
Senel S., Capan Y., Sargon M. F., Ikinci G., Solpan D., Guven O., Bodde H., Hincal A.
JOURNAL OF CONTROLLED RELEASE, vol.45, no.2, pp.153-162, 1997 (SCI-Expanded)
- LX. **Design and evaluation of sustained-release and buccal adhesive propranolol hydrochloride tablets**
Taylan B., Capan Y., Guven O., Kes S., Hincal A.
JOURNAL OF CONTROLLED RELEASE, vol.38, no.1, pp.11-20, 1996 (SCI-Expanded)
- LXI. **FORMULATION AND IN-VITRO IN-VIVO EVALUATION OF BUCCOADHESIVE MORPHINE-SULFATE TABLETS**
ANLAR S., ÇAPAN Y., GUVEN O., GOGUS A., DALKARA T., HINCAL A.
PHARMACEUTICAL RESEARCH, vol.11, no.2, pp.231-236, 1994 (SCI-Expanded)
- LXII. **FORMULATION, BIOAVAILABILITY, AND PHARMACOKINETICS OF SUSTAINED-RELEASE POTASSIUM-CHLORIDE TABLETS**
ŞENEL S., ÇAPAN Y., DALKARA T., INANC N., HINCAL A.
PHARMACEUTICAL RESEARCH, vol.8, no.10, pp.1313-1317, 1991 (SCI-Expanded)
- LXIII. **FORMULATION AND INVITRO-INVIVO EVALUATION OF SUSTAINED-RELEASE LITHIUM-CARBONATE TABLETS**
CIFTCI K., ÇAPAN Y., OZTURK O., HINCAL A.
PHARMACEUTICAL RESEARCH, vol.7, no.4, pp.359-363, 1990 (SCI-Expanded)
- LXIV. **INFLUENCE OF TECHNOLOGICAL FACTORS ON FORMULATION OF SUSTAINED-RELEASE TABLETS**
ÇAPAN Y.
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, vol.15, no.6-7, pp.927-956, 1989 (SCI-Expanded)

Articles Published in Other Journals

- I. **Silica nanoparticle synthesis by experimental design for drug and gene delivery applications**

Ultav G., TONBUL H., ŞAHİN A., ÇAPAN Y.

Journal of Research in Pharmacy, vol.27, no.1, pp.12-22, 2023 (Scopus)

- II. **Brain-targeted nanoparticles to overcome the blood-brain barrier**
SEKO I., ŞAHİN A., TONBUL H., ÇAPAN Y.
Journal of Pharmaceutical Technology, vol.1, no.1, pp.26-40, 2020 (Peer-Reviewed Journal)
- III. **Development of paclitaxel and flurbiprofen co-loaded PLGA nanoparticles: understanding critical formulation and process parameters using Plackett-Burman design**
Sahin A., Caban-Toktas S., Tonbul H., Yerlikaya F., AKTAŞ Y., ÇAPAN Y.
ISTANBUL JOURNAL OF PHARMACY, vol.49, no.3, pp.161-166, 2019 (ESCI)
- IV. **Beyine İlaç Taşınması: Truva Atı Teknolojisi**
DOĞAN S., Toktaş S., ÇAPAN Y.
Hacettepe University Journal of the Faculty of Pharmacy, vol.34, no.1, pp.1-16, 2014 (Scopus)
- V. **Brain drug targeting Beyine İlaç Hedeflendirme Stratejileri**
DOĞAN S., Çaban S., ÇAPAN Y.
Hacettepe University Journal of the Faculty of Pharmacy, vol.33, no.2, pp.231-250, 2013 (Scopus)
- VI. **Formulation and in vitro evaluation of paclitaxel loaded nanoparticles Paklitaksel yüklü nanopartiküllerin formülasyonu ve in vitro incelenmesi**
Aygül G., Yerlikaya F., Caban S., VURAL İ., ÇAPAN Y.
Hacettepe University Journal of the Faculty of Pharmacy, vol.33, no.1, pp.25-40, 2013 (Scopus)
- VII. **Beyine İlaç Hedeflendirme Stratejileri**
DOĞAN S. S., TOKTAŞ S., ÇAPAN Y.
Hacettepe University Journal of the Faculty of Pharmacy, 2013 (Peer-Reviewed Journal)
- VIII. **Orally disintegrating tablets ii: In vitro and in vivo evaluations Ağızda dağılan tabletler ii: In vitro ve in vivo değerlendirilmeleri**
Ölmez S. S., VURAL İ., ŞAHİN S., ERTUĞRUL A., ÇAPAN Y.
Hacettepe University Journal of the Faculty of Pharmacy, vol.31, no.1, pp.59-70, 2011 (Scopus)
- IX. **Orally disintegrating tablets i: Preparation technologies Ağızda dağılan tabletler i: Hazırlama teknolojileri**
Ölmez S. S., VURAL İ., ŞAHİN S., ERTUĞRUL A., ÇAPAN Y.
Hacettepe University Journal of the Faculty of Pharmacy, vol.30, no.2, pp.205-230, 2010 (Scopus)
- X. **Pharmaceutical quality by design: Quality by design approach and its elements Farmasötik tasarimla kalite: Tasarimla kalite yaklaşımi ve unsurlari**
YÜCE M., ÇAPAN Y.
Ankara Universitesi Eczacilik Fakultesi Dergisi, vol.39, no.4, pp.369-390, 2010 (Scopus)
- XI. **Etodolac loaded poly (lactide-co-glycolide) nanoparticles: Formulation and in vitro characterization Etodolak yüklü poli (Laktid-ko-glikolid) nanopartikülleri: Formülasyon ve in vitro karakter**
Çirpanli Y., Robineau C., ÇAPAN Y., ÇALIŞ S.
Hacettepe University Journal of the Faculty of Pharmacy, vol.29, no.2, pp.105-114, 2009 (Scopus)
- XII. **Desensitization to allopurinol in a patient with fixed drug eruption**
Damadoglu E., Isik S. R., KARAKAYA G., ÇAPAN Y., KALYONCU A. F.
ASTIM ALLERJİ IMMUNOLOJİ, vol.7, no.3, pp.194-197, 2009 (ESCI)
- XIII. **Preparation and characterization of BSA-loaded alginate microspheres**
ÇETİN M., VURAL İ., ÇAPAN Y., Hincal A. A.
Fabad Journal of Pharmaceutical Sciences, vol.32, no.3, pp.103-107, 2007 (Scopus)
- XIV. **Brain drug targeting Beyne ilaç hedeflendirilmesi**
Çetin M., ÇAPAN Y.
Ankara Universitesi Eczacilik Fakultesi Dergisi, vol.33, no.4, pp.287-305, 2004 (Scopus)
- XV. **Method Validation in Determination of Mitoxantrone by HPLC**
Bozdağ S., ÇAPAN Y., VURAL İ., Hincal A. A.
Acta Pharmaceutica Turcica, vol.46, no.1, pp.43-47, 2004 (Scopus)
- XVI. **Preparation and characterization of poly(D,L-lactide-co-glycolide) microspheres for controlled**

release of human growth hormone

ÇAPAN Y., Jiang G., Giovagnoli S., Na K., DeLuca P. P.

AAPS PharmSciTech, vol.4, no.2, 2003 (Scopus)

- XVII. **Mitoxantrone loaded poly(DL-lactide-co-glycolide) microspheres for treatment of brain tumors I. formulation and release characteristics**
PEHLİVAN S., ÇAPAN Y., VURAL İ., Hincal A., DeLuca P.
Technology and Health Care, vol.10, no.3-4, pp.353-355, 2002 (Scopus)
- XVIII. **Starch microspheres: Importance, preparation and applications Nisasta mikroküreleri: Onemi - Hazirlanisi - Uygulanmalari**
Selek H., ÇAPAN Y., Kas H.
Fabad Journal of Pharmaceutical Sciences, vol.24, no.1, pp.31-42, 1999 (Scopus)
- XIX. **Formulation and in vitro/in vivo evaluation of buccal bioadhesive captopril tablets**
Yaziksiz Işcan Y., ÇAPAN Y., ŞENEL S., ŞAHİN M. G., Kes S., Duchêne D., Hincal A.
S.T.P. Pharma Sciences, vol.8, no.6, pp.357-363, 1998 (Scopus)
- XX. **Formulation and comparative bioavailability of conventional and sustained release furosemide tablets**
Farshi F., ÇAPAN Y., Kes S., Hincal A.
S.T.P. Pharma Pratiques, vol.5, no.5, pp.361-366, 1995 (Scopus)
- XXI. **Topographical dissolution characterization for sustained release furosemide tablets**
Farshi F., ÇAPAN Y., Atilla Hincal A.
Acta Pharmaceutica Turcica, vol.36, no.4, pp.118-127, 1994 (Scopus)
- XXII. **Physico-chemical and bioadhesive properties of polyacrylamic acid polymers**
Anlar S., ÇAPAN Y., Hincal A.
Pharmazie, vol.48, no.4, pp.285-287, 1993 (Scopus)
- XXIII. **Formulation and efficacy of sustained-release theophylline tablets**
ÇAPAN Y., Capan N., Kas H., Atıkcın S., Baser Y., Hincal A.
S.T.P. Pharma Sciences, vol.2, no.2, pp.169-173, 1992 (Scopus)
- XXIV. **Factors affecting the formulation of sustained release potassium chloride tablets**
ŞENEL S., ÇAPAN Y., Hincal A.
Pharmazie, vol.46, no.11, pp.792-795, 1991 (Scopus)
- XXV. **Influence of filler excipients on the release rate of sustained release lithium carbonate tablets**
ÇAPAN Y., Ciftci K., Atilla Hincal A.
European Journal of Pharmaceutics and Biopharmaceutics, vol.37, no.1, pp.14-18, 1991 (Scopus)
- XXVI. **Evaluation of sustained release lithium carbonate tablets from urine**
Ciftci K., ÇAPAN Y., Hincal A.
S.T.P. Pharma Sciences, vol.1, no.4, pp.272-275, 1991 (Scopus)
- XXVII. **Sustained release isoniazid tablets II. In vivo evaluation**
ÇAPAN Y., Kas S., ÖNER L., Bulut-Oner F., Hincal A.
Sciences Techniques et Pratiques Pharmaceutiques, vol.6, no.7, pp.460-463, 1990 (Scopus)
- XXVIII. **Sustained release isoniazid tablets I-formulation and in vitro evaluation**
Bulut-Oner F., ÇAPAN Y., Kas S., ÖNER L., Hincal A.
Farmaco, vol.44, no.7-8, pp.739-752, 1989 (Scopus)
- XXIX. **Formulation and in vitro-in vivo evaluations on sustained release acetylsalicylic acid tablets**
ÇAPAN Y., ŞENEL S., ÇALIŞ S., Takka S., Hincal A.
Pharmazeutische Industrie, vol.51, no.4, pp.443-448, 1989 (Scopus)
- XXX. **Formulation studies of the wetting solutions for hard contact lenses. 1. Microbiological studies Sert kontakt lens islatma çözeltileri üzerinde formülasyon çalışmaları. 1. Mikrobiyolojik çalışmalar.**
Unlü N., ÇAPAN Y., Yuluğ N.
Mikrobiyoloji Bulteni, vol.15, no.3-4, pp.179-187, 1981 (Scopus)

Refereed Congress / Symposium Publications in Proceedings

- I. **Lokman Hekim Üniversitesi Eczacılık Fakültesi öğrenci asistanlığı uygulaması**
Gümüşel B., Özden M. S., Onur F., Çapan Y., Gümüşel B., Yıldız S., Konuklugil B., Yiğit D., Erikçi A., Eroğlu E., et al.
III. Ulusal Eczacılık Eğitimi ve Akreditasyon Kongresi, Ankara, Turkey, 17 - 19 November 2021, pp.37
- II. **LOKMAN HEKİM ÜNİVERSİTESİ ECZACILIK FAKÜLTESİNDE PANDEMİ KOŞULLARINDA EĞİTİM UYGULAMALARI**
Çapan Y.
III. ECZACILIK EĞİTİMİ VE AKREDİTASYON KONGRESİ, 17 - 19 November 2021, pp.52
- III. **Folic Acid Conjugated Mesoporous Silica Nanoparticles For Enhanced Therapeutic Efficacy of Doxorubicin In Breast Cancer**
TONBUL H., AKBAŞ S., ULTAV G., ŞAHİN A., TAVUKCUOĞLU E., AKTAŞ Y., ESENDAĞLI G., ÇAPAN Y.
8th BBBB Conference on Pharmaceutical Sciences, 14 - 16 October 2019, vol.1, pp.184-186
- IV. **PREPERATION, CHARACTERIZATION, CYTOTOXICITY EVALUATIONS OFFOLIC ACID CONJUGATED MESOPOROUS SILICA NANOPARTICLES**
TONBUL H., ultav g., akbas s., sahin a., tavukcuoglu e., AKTAŞ Y., ESENDAĞLI G., ÇAPAN Y.
19th InternationalPharmaceutical Technology Symposium-IPTS 2018, 17 - 19 September 2018
- V. **DEVELOPMET AND EVALUATION OF SILICA NANOPARTICLES USING A QUALITY BY DESIGN APPROACH**
TONBUL H., AKBAŞ S., ULTAV G., ŞAHİN A., AKTAŞ Y., ÇAPAN Y.
EUFEPS Annual Meeting 2018, 24 - 26 May 2018
- VI. **IN VITRO EVALUATION OF PACLITAXEL LOADED MESOPOROUS SILICA NANOPARTICLES**
TONBUL H., AKBAŞ S., ULTAV G., ŞAHİN A., AKTAŞ Y., ÇAPAN Y.
EUFEPS Annual Meeting 2018, 24 - 26 May 2018
- VII. **Synthesis and Characterization of Silica Nanoparticles: Obtaining nanoparticles smaller than 100 nm**
TONBUL H., AKBAŞ S., ULTAV G., ŞAHİN A., KAYNAK M. S., AKTAŞ Y., ÇAPAN Y.
2nd International Gazi Symposium Series, 11 - 13 October 2017
- VIII. **Transferrine hedeflendirilmiş paklitaksel yüklü PLGA nanopartiküllerinin meme kanserindeki etkinliği**
TONBUL H., ŞAHİN A., ÖZTÜRK N., VURAL İ., KAYNAK M. S., ÇAPAN Y.
1. Anadolu Üniversitesi Eczacılık Fakültesi Sempozyumu (ANES), Turkey, 1 June - 02 January 2017
- IX. **Comparing Intracellular Delivery of PLGA and Chitosan Nanoparticles Lessons and Challenges**
ŞAHİN A., Yerlikaya F., AKTAŞ Y., ESENDAĞLI G., ÇAPAN Y.
GPEN 2016, 9 - 12 November 2016
- X. **Drug Delivery with Targeted Nanoparticles: in Vitro and in Vivo Evaluation Methods.**
ÇAPAN Y.
17th International Pharmaceutical Technology Symposium, 18 - 21 October 2016
- XI. **Co Encapsulation Studies of Doxorubicin and Celecoxib in PLGA Nanoparticles**
Kozlu S., ŞAHİN A., Sevda Ş., Yerlikaya F., ÇAPAN Y.
18th International Pharmaceutical Technology Symposium-IPTS 2016, 18 September 2016 - 21 September 2016
- XII. **Development and in vitro evaluation of transferrin targeted PLGA nanoparticle**
TONBUL H., ŞAHİN A., KAYNAK M. S., ÇAPAN Y.
18th International Pharmaceutical Technology Symposium-IPTS 2016, 19 - 21 September 2016
- XIII. **Intracellular delivery and intraperitoneal retention of different sized PLGA nanoparticles prepared by nanoprecipitation method**
ŞAHİN A., ESENDAĞLI G., Fırat Y., Serhat K., Yöyen Ermis D., Horzum U., AKTAŞ Y., Khan M., Couvreur P., ÇAPAN Y.
18th International Pharmaceutical Technology Symposium-IPTS 2016, 18 - 21 September 2016
- XIV. **Brain drug delivery**
ÇAPAN Y.
International Conference on Advances in the Area of Bioequivalence, Pharmaceutical Technology Symposium, 14 November 2015

- XV. **Effects of Combined Surfactants in the Formulation of Docetaxel Loaded PLGA Nanoparticles**
Abdykerim Kyzy G., Çaban S., ŞAHİN A., ÇAPAN Y.
AAPS Annual Meeting 2015, 25 - 29 October 2015
- XVI. **Determination of Critical Parameters of Paclitaxel and Flurbiprofen Co Loaded PLGA Nanoparticles Prepared By Nanoprecipitation**
ŞAHİN A., Çaban S., Abdykerim Kyzy G., Yerlikaya F., AKTAŞ Y., ÇAPAN Y.
AAPS Annual Meeting 2015, 25 - 29 October 2015
- XVII. **Particle Size Optimization of Ibuprofen Loaded PLGA Nanoparticles Using Box Behnken Design**
ŞAHİN A., Çaban S., AKTAŞ Y., ÇAPAN Y.
AAPS 2015 Annual Meeting, 25 - 29 October 2015
- XVIII. **Nanoscale drug delivery systems and the blood brain barrier**
ÇAPAN Y.
International Multidisciplinary Symposium on Drug Research & Development 2015, 15 - 17 October 2015
- XIX. **Nanoscale drug delivery systems and the blood-brain barrier**
ÇAPAN Y.
17th International Pharmaceutical Technology Symposium, 8 - 10 September 2014
- XX. **Nanoparticulate Drug Delivery Systems Pharmaceutical Applications**
ÇAPAN Y.
IAEA Regional Training Course on "Radiation Synthesis and Characterization of Nanostructures, 8 - 12 November 2010
- XXI. **Brain Drug Targeting**
ÇAPAN Y.
15th International Pharmaceutical Technology Symposium, 13 - 15 October 2010
- XXII. **The importance of particle size analysis: Its role in pharmaceutical development**
ÇAPAN Y.
United States Pharmacopeia and Ekin Kimya 4th Science Standards Symposium, 15 October 2010
- XXIII. **Brain Drug Targeting**
ÇAPAN Y.
6th International Biomedical Science and Technology Symposium, 28 September - 02 October 2010
- XXIV. **Brain Drug Targeting IMPPS-3**
ÇAPAN Y.
Third International Meeting On Pharmacy Pharmaceutical Sciences, 9 - 12 June 2010
- XXV. **Evaluation of the products with the same formula on the point of pharmaceutical technology**
ÇAPAN Y.
Turkish Society of Hematology Updating on Hematological Oncology Meeting, 6 - 09 May 2009
- XXVI. **Bioavailability Bioequivalence**
ÇAPAN Y.
BioInternational 2008, 22 - 24 October 2008
- XXVII. **Blood Brain Barrier Delivery with Molecular Trojan Horses**
ÇAPAN Y.
14th International Pharmaceutical Technology Symposium, 6 - 10 September 2008
- XXVIII. **Perspectives in drug release from micro- and nanoparticulate drug delivery systems**
ÇAPAN Y.
14th International Pharmaceutical Technology Symposium, 6 - 10 September 2008
- XXIX. **Bioavailability and Bioequivalence**
ÇAPAN Y.
34. National Haematology Congress, 10 - 11 August 2008
- XXX. **Technological Factors Influencing BA / BE**
ÇAPAN Y.
FATUM Symposium on Bioavailability / Bioequivalence and Regulatory Issues, 17 - 18 March 2008
- XXXI. **Recent Advances in Brain Drug Delivery**

- ÇAPAN Y.
16th International Symposium on Microencapsulation, 09 September 2007
- XXXII. **BE practice and issues in Turkey**
ÇAPAN Y.
Biointernational 2005, 24 - 25 October 2005
- XXXIII. **An overview of dissolution and bioequivalence**
ÇAPAN Y.
Hands-On-Dissolution Workshop, 10 - 11 October 2005
- XXXIV. **Nanoparticle technology its Pharmaceutical Applications**
ÇAPAN Y.
FIP Meeting, 01 January 2005
- XXXV. **Preparation and Characterization of Basic Fibroblast Growth Factor (bFGF)-Loaded Microparticulate Drug Delivery Systems,**
ÇETİN M., ÇAPAN Y., VURAL İ., GÜRSOY R. N., DALKARA T., Cuine A., HINCAL A.
2004 AAPS Annual Meeting and Exposition, Maryland, United States Of America, 31 October 2004
- XXXVI. **Mitoxantrone Loaded Albumin Microspheres and Cytotoxicity Against Acute Promyelocytic Leukemia Cells**
ÇAPAN Y.
7th US-Japan Symposium on Drug Delivery systems, 14 - 19 December 2003
- XXXVII. **Dissolution rate, Influence of Technological Parameters on Dissolution Rate, and Evaluation of Dissolution Rate Data**
ÇAPAN Y.
7th International Symposium on Pharmaceutical Sciences, 23 - 27 June 2003
- XXXVIII. **Overview of Bioavailability/Bioequivalence Studies in Turkey**
ÇAPAN Y.
ISHDRLP 2 (International Symposium on Harmonization and Drug Registration and Licensing Procedures), 9 - 11 September 2001
- XXXIX. **Preparation and Characterization of Poly (D,L-lactide-co-glycolide) Microspheres For Controlled Release of Poly (L-Lysine) Complexed Plasmid DNA**
ÇAPAN Y.
8th Biomedical Science and Technology Symposium, 5 - 08 September 2000

Supported Projects

- Mut Aşkun M., Çapan Y., Esendağlı G., TUBITAK Project, Beyine Hedeflendirilmiş Bevasizumab Yüklü Nanopartiküler İlaç Taşıyıcı Sistemlerin Hazırlanması Ve Etkinliklerinin In Vitro-In Vivo Değerlendirilmesi, 2018 - 2021
- ÇAPAN Y., Ultav G., AKBAŞ S., Project Supported by Higher Education Institutions, Meme kanseri tedavisinde kullanılmak üzere farklı boyutlara sahip pH Duyarlı mezogözenekli silika nanopartiküllerinin geliştirilmesi optimizasyonu ve etkinliklerinin in vitro testlerle değerlendirilmesi, 2016 - 2017
- ÇAPAN Y., Project Supported by Higher Education Institutions, 2016 AAPS Kongresine Katılım Desteği, 2016 - 2016
- ÇAPAN Y., Project Supported by Higher Education Institutions, Farmasötik Teknoloji Alanındaki Gelişmelerin Takip Edilmesi ve Uluslararası Nitelikte Bilgi Paylaşımının Sağlanması, 2015 - 2016
- ÇAPAN Y., TUBITAK Project, Kan Beyin Engelini Geçişte Taşıyıcı Sistem Özelliklerinin Optimizasyonu Ve Geçiş Mekanizmalarının İncelenmesi, 2014 - 2016
- ÇAPAN Y., TUBITAK Project, Kan Beyin Engelini Geçişte Taşıyıcı Sistem Özelliklerinin Optimizasyonu ve Geçiş Mekanizmalarının İncelenmesi, 2014 - 2016
- ÇAPAN Y., ŞAHİN A., Project Supported by Higher Education Institutions, Beyin Kanseri Üzerinde Etkili Nanopartikül Formülasyonlarının Geliştirilmesi ve İn Vitro Etkinliklerinin Değerlendirilmesi, 2014 - 2015
- ÇAPAN Y., Project Supported by Higher Education Institutions, Beyin Kanseri Üzerinde Etkili Nanopartikül Formülasyonlarının Geliştirilmesi ve İn Vitro Etkinliklerinin Değerlendirilmesi, 2014 - 2015

Çapan Y., Kobi, İmatinib çalışmaları, 2013 - 2015

Çapan Y., Kobi, İmatinib mezilat tablet ve kapsüllerinin kalite kontrolü kapsamında etkin madde, impürite solvat ve diğer katı dozaj formlarına yönelik arařtırmaların yapılması, sonuçlara yönelik önerilerin geliştirilmesi ve raporlanması, 2012 - 2014

ÇAPAN Y., TUBITAK Project, Nöroproteksiyonda nanoteknolojik yaklaşımlar, 2011 - 2013

ÇAPAN Y., TUBITAK Project, Antikaspaz-3 Ajanlar ve Bazik Fibroblast Büyüme Faktörü (bFGF)' nün Serebral İskemideki Sinerjistik Nöroprotektif Rolü, 2009 - 2010

ÇAPAN Y., TUBITAK Project, Serebral İskemi Tedavisinde Kullanılmak Üzere Peptid,Protein veya Oligonükleotid İçeren Nanopartiküler İlaç Taşıyıcı Sistemlerin Tasarımı ve in vitro Etkinliklerinin Arařtırılması, 2005 - 2007

Metrics

Publication: 152

Citation (WoS): 1698

Citation (Scopus): 2336

H-Index (WoS): 22

H-Index (Scopus): 25